Literature DB >> 6547167

Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.

M F da Cunha, M L Meistrich, L M Fuller, J H Cundiff, F B Hagemeister, W S Velasquez, P McLaughlin, S A Riggs, F F Cabanillas, P G Salvador.   

Abstract

The sperm production of 25 patients with Hodgkin's disease treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy was studied retrospectively. All but two patients also received radiotherapy treatment to pelvic and/or non-pelvic fields. Sperm counts were obtained from patients treated either with three or fewer (MOPP-2 group) or with five or more (MOPP-6 group) chemotherapy cycles. Recovery of spermatogenesis following treatment-induced azoospermia was significantly higher among the MOPP-2 patients (Mann-Whitney rank sum test, p = 0.001). Patients in this group who did not receive pelvic irradiation appeared to have greater recovery rates (p = 0.06). The results suggest that three cycles of MOPP chemotherapy represent a maximum exposure compatible with the recovery of spermatogenesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547167     DOI: 10.1200/JCO.1984.2.6.571

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.

Authors:  Daniel M Green; Wei Liu; William H Kutteh; Raymond W Ke; Kyla C Shelton; Charles A Sklar; Wassim Chemaitilly; Ching-Hon Pui; James L Klosky; Sheri L Spunt; Monika L Metzger; DeoKumar Srivastava; Kirsten K Ness; Leslie L Robison; Melissa M Hudson
Journal:  Lancet Oncol       Date:  2014-09-16       Impact factor: 41.316

2.  Relationship between spermatogonial stem cell survival and testis function after cytotoxic therapy.

Authors:  M L Meistrich
Journal:  Br J Cancer Suppl       Date:  1986

Review 3.  Early-stage Hodgkin's disease: current approaches to treatment.

Authors:  J J Rusthoven; R MacKenzie
Journal:  Can Med Assoc J       Date:  1985-08-01       Impact factor: 8.262

Review 4.  Anticancer chemotherapeutic agents and testicular dysfunction.

Authors:  Kohei Yamaguchi; Masato Fujisawa
Journal:  Reprod Med Biol       Date:  2011-03-17

Review 5.  Educational paper: the effect of cancer therapy on fertility, the assessment of fertility and fertility preservation options for pediatric patients.

Authors:  Jill P Ginsberg
Journal:  Eur J Pediatr       Date:  2010-12-04       Impact factor: 3.183

Review 6.  Adverse effects of common medications on male fertility.

Authors:  Mary K Samplaski; Ajay K Nangia
Journal:  Nat Rev Urol       Date:  2015-06-23       Impact factor: 14.432

7.  Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.

Authors:  C Bokemeyer; H J Schmoll; J van Rhee; M Kuczyk; F Schuppert; H Poliwoda
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

8.  Hodgkin's disease in adults: the challenge.

Authors:  T A Lister
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

Review 9.  Fertility preservation and management of gonadal failure associated with lymphoma therapy.

Authors:  Simon J Howell; Stephen M Shalet
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

10.  Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Toana Kawashima; Marilyn Stovall; Wendy Leisenring; Charles A Sklar; Ann C Mertens; Sarah S Donaldson; Julianne Byrne; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.